Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (151-160 of 314) with videos related to

Pageof 32
Sort By:
The Journal of Clinical Investigation|January 17, 2023
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatmentVíctor A Arrieta, Crismita Dmello, Daniel J McGrail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomideMonika E Hegi, Annie-Claire Diserens, Sophie Godard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumorJohn O Prior, Michael Montemurro, Maria-Victoria Orcurto, et al.
Bioelectrochemistry (Amsterdam, Netherlands)|October 28, 2022
Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapyChristoph Pohling, Ha Nguyen, Edwin Chang, et al.
Oncogene|April 3, 2020
Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growthRexhep Uka, Christian Britschgi, Anja Krättli, et al.
Neuro-Oncology Advances|January 7, 2022
Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent mannerDaniel Y Zhang, Andrew Gould, Hannah C Happ, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 10, 2010
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planningElena Musat, Erik Roelofs, Raquel Bar-Deroma, et al.
The Lancet. Oncology|August 11, 2012
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trialAnnika Malmström, Bjørn Henning Grønberg, Christine Marosi, et al.
BMC Cancer|January 13, 2018
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyAlexander R Siebenhüner, Heike Seifert, Helga Bachmann, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2008
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changesKarin Ribi, Jürg Bernhard, Jan C Schuller, et al.
Pageof 32

Showing results (151-160 of 314) with videos related to

Sort By:
Pageof 32
The Journal of Clinical Investigation|January 17, 2023
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatmentVíctor A Arrieta, Crismita Dmello, Daniel J McGrail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomideMonika E Hegi, Annie-Claire Diserens, Sophie Godard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumorJohn O Prior, Michael Montemurro, Maria-Victoria Orcurto, et al.
Bioelectrochemistry (Amsterdam, Netherlands)|October 28, 2022
Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapyChristoph Pohling, Ha Nguyen, Edwin Chang, et al.
Oncogene|April 3, 2020
Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growthRexhep Uka, Christian Britschgi, Anja Krättli, et al.
Neuro-Oncology Advances|January 7, 2022
Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent mannerDaniel Y Zhang, Andrew Gould, Hannah C Happ, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 10, 2010
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planningElena Musat, Erik Roelofs, Raquel Bar-Deroma, et al.
The Lancet. Oncology|August 11, 2012
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trialAnnika Malmström, Bjørn Henning Grønberg, Christine Marosi, et al.
BMC Cancer|January 13, 2018
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyAlexander R Siebenhüner, Heike Seifert, Helga Bachmann, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2008
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changesKarin Ribi, Jürg Bernhard, Jan C Schuller, et al.
Pageof 32